https://www.selleckchem.com/products/Eloxatin.html
0 to 6.0], 8.5 [8.0 to 10.3] and 11.0 [9.0 to 12.5] injections by 6, 12 and 18 months, respectively. CONCLUSIONS The visual outcomes achieved with a treat-and-extend protocol in this study were similar to the pivotal trials of aflibercept for CMO secondary to CRVO, which used monthly and then as-needed protocols. TRIAL REGISTRATION Australian and New Zealand Clinical Trials Registry, registration number ACTRN12615000417583, 01/05/2015.BACKGROUND Patients with fibrotic interstitial lung disease (FILD) often experience gas exchange abnor
Like
Comment
Share
